Highest-materiality recent filing
Hepion Pharma CEO Kaouthar Lbiati resigns; Gary Stetz named interim CEO
CEO Dr. Kaouthar Lbiati resigned effective March 16, 2026, for personal reasons.
Hepion Pharmaceuticals names Kaouthar Lbiati CEO effective Jan 8, 2026; salary $350K
Dr. Kaouthar Lbiati appointed CEO effective Jan 8, 2026, per Board approval on Jan 13, 2026.
Hepion Pharmaceuticals CFO John Brancaccio resigns; interim CFO named
John Brancaccio resigned as CFO and director effective June 30, 2025, for personal reasons.
Hepion shareholders reject reverse stock split amendment at 2025 annual meeting
Reverse stock split proposal (1:5 to 1:20) failed with 2.25M for, 3.70M against; not approved.
Hepion appoints director Kaouthar Lbiati as interim CEO effective June 16
Dr. Kaouthar Lbiati, a board member since June 2022, appointed interim CEO effective June 16, 2025.
Hepion sells Rencofilstat assets to Panetta for nominal fee; stockholders get CVR milestones
Sold all patent assets, knowhow, clinical data, and drug product for Rencofilstat to Panetta Partners for nominal amount.
Hepion delisted from Nasdaq; pivots to diagnostics via New Day license
Received Nasdaq delisting notice for failing to maintain $1.00 bid price and being deemed a public shell; trading suspended May 13, 2025.
Nasdaq deems Hepion a 'public shell' as additional delisting basis; hearing April 29
Received Nasdaq notice on April 15, 2025, alleging company is a 'public shell' and continued listing unwarranted.
Hepion receives Nasdaq delisting notice as bid price falls below $0.10 for 10 days
Stock closed below $0.10 for 10 consecutive business days triggering the Low Priced Stocks Rule.
Hepion shareholders approve reverse stock split (1:10-1:50) at annual meeting
All four director nominees elected (Brancaccio, Block, Lbiati, Purcell) with majority 'For' votes.
Notice dated January 14, 2025 from Nasdaq for failing to hold annual shareholders' meeting within 12 months of fiscal year end.
Hepion terminates merger with Pharma Two B; special meeting cancelled
Merger Agreement with Pharma Two B Ltd. terminated mutually on Dec 10, 2024.
Stockholders' deficit of ($406,685) as of Sept 30, 2024 triggers Nasdaq Listing Rule non-compliance.
Hepion Pharmaceuticals receives Nasdaq deficiency notice for bid price below $1.00
Notice received Sept. 3, 2024; bid price below $1.00 for 30 consecutive business days.
Hepion Pharma's interim CEO/CFO resigns; executive chairman takes over
John Cavan departed as interim CEO and CFO on August 5, 2024 for personal reasons.
Hepion will merge with Pharma Two B Ltd.; existing Hepion shareholders receive ordinary shares of Parent.
Hepion raises $2.06M via warrant inducement, reduces exercise prices and issues new warrants
Holders of 980,393 Series B warrants will exercise at reduced price of $2.10/share, raising ~$2.06M gross proceeds.
Hepion Pharmaceuticals dismisses BDO, appoints Grassi as new auditor
BDO dismissed as independent auditor effective Jan 1, 2024; Grassi Advisors engaged to audit FY 2023 financials.
Hepion CEO resigns, interim CEO named; restructuring plan to cut costs 60%
Dr. Robert Foster resigns as CEO and director for personal reasons, effective immediately.
Hepion Pharmaceuticals raises $5.0M in registered direct offering with warrants
Gross proceeds $5.0M from sale of 980,393 shares (or equivalents) at $5.10/share plus warrants.
Hepion Pharmaceuticals enters $24M ATM equity offering with Cantor Fitzgerald
ATM sales agreement with Cantor Fitzgerald allows Hepion to sell up to $24M of common stock at market prices.
Phase 2 trial met primary endpoint: 225 mg rencofilstat reduced DSI by 1.62 units (p<0.05) and SHUNT by 2.8% (p<0.05).
Hepion Pharmaceuticals Raises $20M via Private Placement of Convertible Preferred Stock
Offering includes 1,900,000 Series F and 100,000 Series G shares at $9.50 each.
Hepion receives Nasdaq delisting notice for bid price below $1.00 per share
Notice received June 3, 2022; stock continues trading under symbol HEPA.
Hepion reports positive Phase 2a AMBITION NASH data; plans three Phase 2/2b trials starting Q3 2022
Phase 2a AMBITION NASH trial met primary endpoints: safety, tolerability, PK; no serious adverse events.
Phase 2a NASH trial (AMBITION) met safety endpoints; showed ALT and Pro-C3 reductions over 28 days.
Hepion Pharma gets FDA IND clearance for CRV431 in liver cancer (HCC), enabling direct Phase 2 start
FDA accepted IND for CRV431 for hepatocellular carcinoma; allows Phase 2 trial to begin without Phase 1.
On June 3, 2025, the Board of Directors of Hepion Pharmaceuticals, Inc., a Delaware corporation (the “ Company ”), approved the appointment of Dr. Kaouthar Lbiati, a director of the Company, as interim Chief Executive Officer, effective June 16, 2025.
On August 6, 2024, John Brancaccio, the Company’s executive chairman was appointed the interim Chief Executive Officer and interim Chief Financial Officer of the Company.
On August 5, 2024, John Cavan, the interim Chief Executive Officer and Chief Financial Officer of Hepion Pharmaceuticals, Inc. (the “Company”) left the Company for personal reasons.
On March 5, 2024, the Board of Directors of Hepion Pharmaceuticals, Inc. (the “Company”) appointed Michael Purcell as a director of the Company.
Dr. Jacob was Chairman of the Company and the Board of Directors appointed John Brancaccio as Chairman.
On February 20, 2024, Dr. Gary Jacob resigned from the Board of Directors of Hepion Pharmaceuticals, Inc. (the “Company”) for personal reasons.
On February 7, 2024, Anand Reddi resigned from the Board of Directors of Hepion Pharmaceuticals, Inc.
the Board of Directors appointed John Cavan, the Company’s Chief Financial Officer, as interim Chief Executive Officer.
Dr. Robert Foster, the Company's CEO, resigned from the Company as CEO for personal reasons, effective immediately.
Dr. Peter Wijngaard resigned from the Board of Directors of the Company.
On September 6, 2023, the Company appointed Stephen Harrison, M.D., the Company’s current Chairman of the Company’s Scientific Advisory Board, as Consultant Medical Director.
On August 30, 2023, Dr. Todd Hobbs, the Chief Medical Officer (“CMO”), of Hepion Pharmaceuticals, Inc. (the “Company”) provided notice to the Company of his resignation as CMO, effective September 29, 2023.
Max materiality 0.90 · Median 0.60 · Most common event other_material